Group 1 - The A-share market experienced significant volatility, with a peak increase of 45 points that was later erased, resulting in the longest upper shadow line of the year, indicating uncertainty in market direction [1] - The analysis suggests that the three main driving forces for the market remain intact: U.S. monetary easing, potential relaxation in the domestic real estate sector, and declining interest rates [2][3] - The domestic real estate sector is expected to see a positive impact from potential policy relaxations, which could stabilize the market and benefit related stocks [2][3] Group 2 - The recent adjustment in the banking sector, which saw a decline of 1.91%, was a significant factor in the market's volatility, but the long-term outlook remains positive due to supportive policies for insurance companies [3][4] - New regulations for insurance companies allow for a longer evaluation period of 3 to 5 years, reducing the pressure to achieve short-term performance and encouraging long-term investments in the A-share market [4][6] - The potential increase in insurance funds' investment in the A-share market could lead to an influx of approximately 3.5 trillion yuan, significantly stabilizing the market [7][8]

Core Viewpoint - The bull market is not over, and the upward trend of the market remains intact due to three main reasons [1][2]. Group 1: Market Dynamics - The banking sector's significant drop allows for the inflow of funds into small and mid-cap stocks, leading to a broad market rally [1]. - Despite the Shanghai Composite Index showing a "doji" candlestick pattern, the Shenzhen Component and ChiNext Index exhibited healthy trends, indicating that major funds are shifting towards the technology sector [1]. - Today's trading volume exceeded 1.7 trillion, marking the fifth occurrence this year, which is crucial for market confidence and potential upward movement [2]. Group 2: Sector Performance - The real estate, photovoltaic, and glass sectors have reached a temporary peak, while the non-involution sectors are expected to benefit from rising prices, particularly in the rare metals sector [2]. - The innovation drug sector is anticipated to continue reaching new highs due to multiple positive developments [2]. - The new regulations from the Shenzhen Stock Exchange will remove underperforming stocks from the ChiNext Index, setting the stage for a potential surge in the technology sector next week [2].

Market Overview - The A-share market experienced a significant increase with a trading volume of 1.7 trillion, indicating a strong market activity [1] - The market showed a "short squeeze" type of rally in the morning but faced a pullback in the afternoon, suggesting volatility in the trading session [1] Technical Analysis - The key level to watch is 3491 points, which is identified as a prosperity line; a drop below this level on Monday could signal the end of the current rebound phase [2] - Despite potential pullbacks, the overall trend remains bullish on a weekly basis, indicating that the larger upward movement is not yet over [2][3] Sector Performance - The focus remains on the ChiNext and Shanghai Composite indices, which are showing a strong upward trend, while the Sci-Tech 50 index is lagging behind [3] - Recent market performance highlights sectors such as solar energy and financial brokerage firms, which are experiencing notable gains [3]

Group 1 - The core viewpoint indicates that the market experienced a significant increase in indices, but a subsequent decline in bank stocks suggests potential risks due to rapid price increases [1] - The rare simultaneous inflow of institutional and main funds into aggressive sectors indicates a possible bullish trend for small-cap stocks next week [1] - The performance of the securities sector is crucial, as it remained stable during the market downturn, supporting small-cap stocks [1] Group 2 - The rare occurrence of a strong performance in the rare earth sector, driven by positive news and price increases, suggests it may continue to perform well next week [1] - The technology sector, particularly the Sci-Tech 50 index, has lagged but shows signs of recovery, potentially leading to a rebound in tech stocks [1] - The market sentiment may shift towards small-cap stocks if banks continue to decline, indicating a possible resurgence for mid and small-cap stocks [1]

Group 1 - The core viewpoint indicates that the stock of XGIMI Technology (688696) is currently showing a weak overall score of 35.52, suggesting a cautious investment outlook [1] - The main cost analysis reveals that the current main cost is 110.50 CNY, with a 5-day average cost of 106.83 CNY, a 20-day average of 112.82 CNY, and a 60-day average of 118.03 CNY, indicating a downward trend in costs over time [1] - The stock has not experienced any limit-up or limit-down events in the past year, reflecting a stable trading environment [1] Group 2 - The technical analysis shows a short-term resistance level at 112.52 CNY and a support level at 105.12 CNY, while the mid-term resistance is at 120.53 CNY with the same support level [2] - The current short-term and mid-term trends are unclear, with a need for main funds to choose a direction [2] - On July 11, 2025, the net inflow of main funds was 944.91 million CNY, accounting for 9% of the total transaction volume, indicating a positive sentiment among larger investors [2]

Group 1 - The core viewpoint indicates that Huaxi Biological (688363) has a strong overall score of 50.30, suggesting a robust performance in the market [1] - The main cost analysis shows that the current main cost is 51.41 yuan, with a 5-day average cost of 51.21 yuan and a 20-day average cost of 50.69 yuan, indicating a stable pricing trend [1] - The stock has not experienced any limit-up or limit-down events in the past year, reflecting a stable trading environment [1] Group 2 - The technical analysis identifies a short-term resistance level at 51.52 yuan and a support level at 50.35 yuan, indicating potential price fluctuations within this range [2] - The funding flow data for July 11, 2025, shows a net outflow of 723.83 million yuan from main funds, which is 5% of the total transaction volume, suggesting cautious market sentiment [2] - The related industry sectors, including beauty care, medical devices, cosmetics, and medical beauty, show minor percentage changes, indicating a relatively stable market environment [2]

Group 1 - The overall score for Cambrian (U688256) is 34.67, indicating a weak performance [1] - The main cost analysis shows the following prices: current main cost at 553.98 CNY, 5-day main cost at 539.33 CNY, 20-day main cost at 569.71 CNY, and 60-day main cost at 627.98 CNY [1] - In the past year, the stock has hit the upper limit 5 times and has not hit the lower limit [1] Group 2 - The short-term resistance level is at 547.47 CNY, while the short-term support level is at 523.50 CNY [2] - The stock price has broken through the short-term resistance level, indicating potential short-term strength, while the medium-term trend remains unclear [2] - On July 11, 2025, the net inflow of main funds was 114,177.99 million CNY, accounting for 18% of the total transaction amount [2]

Group 1 - The market has not shown any signals indicating the end of the upward trend, and the recent fluctuations are seen as a consolidation behavior, suggesting that the market can continue to rise next week [1][2] - Despite the pullback in the major indices, there has been no significant outflow of capital from the market, indicating that buying pressure remains strong [1] - The market is still above the 5-day moving average and key breakout levels, which supports the continuation of the upward trend [1] Group 2 - The recent pullback is primarily observed in the banking sector, which has experienced significant gains recently, while other sectors such as metals, brokerage, rare earths, and pharmaceuticals continue to show upward momentum [2] - The presence of strong buying interest in various sectors suggests that the overall market trend is not ending, but rather experiencing a temporary correction [2] - The current market behavior is characterized as a short-term consolidation, with expectations for further upward movement in the coming week [2]

Group 1 - The stock of Baike Biological (688276) has a comprehensive score of 60.55, indicating a strong performance [1] - The main cost analysis shows that the current main cost is 21.78 CNY, with a 5-day main cost of 21.40 CNY, a 20-day main cost of 20.99 CNY, and a 60-day main cost of 20.94 CNY [1] - Over the past year, the stock has not experienced any limit-up or limit-down events [1] Group 2 - On July 11, 2025, the stock saw a net outflow of 55.92 thousand CNY in main funds, which is -1% of the total transaction amount [2] - The stock has a short-term resistance level at 21.58 CNY and a support level at 21.05 CNY, indicating potential for short-term strength if the resistance is broken [2] - The stock is associated with several sectors, including bioproducts (1.53%), virus prevention (0.59%), state-owned enterprise reform (0.51%), and biovaccines (0.70%) [2]

Group 1 - The stock of Wealth Trend (688318) has a comprehensive score of 55.72, indicating a strong performance [1] - The main cost analysis shows the following prices: current main cost at 115.60 CNY, 5-day main cost at 108.76 CNY, 20-day main cost at 107.99 CNY, and 60-day main cost at 100.80 CNY [1] - In the past year, the stock has hit the upper limit of trading three times and has not hit the lower limit [1] Group 2 - Northbound capital data indicates a holding of 1.0691 million shares, accounting for 0.58% of the circulating shares, with a net purchase of 168,800 shares yesterday [1] - The short-term pressure level is at 108.47 CNY, while the short-term support level is at 102.95 CNY; the stock price has broken through the short-term pressure level, suggesting potential short-term strength [2] - The net inflow of main funds on July 11, 2025, was 167.79 million CNY, accounting for 11% of the total transaction amount [2]